• Policy
• Price cut of Faslodex
• by Lee, Tak-Sun Oct 26, 2022 05:50am

• Policy
• Lenvima's PMS results for 6 years
• by Lee, Hye-Kyung Oct 25, 2022 05:45am

• Policy
• How did Zerbaxa get recognized for its benefit?
• by Lee, Tak-Sun Oct 24, 2022 06:08am

• Policy
• Will Gilead reclaim its throne in the HCV drug market?
• by Lee, Tak-Sun Oct 24, 2022 06:08am

• Policy
• Severe AD treatments unlikely to be reimb this year
• by Lee, Tak-Sun Oct 21, 2022 05:48am

• Policy
• Epclusa, a hepatitis C tx, costs 117,030 won
• by Kim, Jung-Ju Oct 21, 2022 05:48am

• Policy
• The head of the MFDS actively agrees with the opinion
• by Lee, Hye-Kyung Oct 21, 2022 05:47am

• Policy
• Xtandi’s use expanded... reimbursement standard changed
• by Lee, Tak-Sun Oct 20, 2022 06:02am

• Policy
• All targets for the benefit reassessment will be negotiated
• by Lee, Tak-Sun Oct 19, 2022 05:48am

• Policy
• Is it possible to benefit from the K-CAB 4th indication?
• by Lee, Tak-Sun Oct 17, 2022 10:52pm